Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Clene Inc
(NQ:
CLNN
)
0.4367
-0.0003 (-0.07%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
429,515
Open
0.4100
Bid (Size)
0.4320 (9)
Ask (Size)
0.4368 (1)
Prev. Close
0.4370
Today's Range
0.4064 - 0.4367
52wk Range
0.2500 - 1.090
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Spotlighted in a Recent ‘From Lab to Launch’ Podcast Release
May 01, 2024
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Presents Findings on Phase 2 VISIONARY-MS LTE at American Academy of Neurology Annual Meeting
May 01, 2024
Via
Investor Brand Network
Performance
YTD
+48.54%
+48.54%
1 Month
+4.00%
+4.00%
3 Month
-11.60%
-11.60%
6 Month
+15.59%
+15.59%
1 Year
-53.64%
-53.64%
More News
Read More
Clene Inc. (NASDAQ: CLNN) Continues Development of Lead Drug Candidate CNM Au8(R) for Neurodegenerative Diseases including Parkinson’s Disease
April 22, 2024
Via
Investor Brand Network
The Analyst Verdict: Clene In The Eyes Of 5 Experts
April 17, 2024
Via
Benzinga
Breaking Down Clene: 4 Analysts Share Their Views
March 13, 2024
Via
Benzinga
Clene: Q4 Earnings Insights
March 13, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
April 19, 2024
Via
Benzinga
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Study Results for CNM-Au8 as Multiple Sclerosis Treatment Presented at AAN Conference
April 17, 2024
Via
Investor Brand Network
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
April 17, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
April 17, 2024
Via
InvestorPlace
Why INVO Bioscience Shares Are Trading Higher By Around 73%; Here Are 20 Stocks Moving Premarket
April 17, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
April 16, 2024
Via
Benzinga
Study Identifies Three Distinct Subtypes of Multiple Sclerosis
April 15, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Looking to Advance Discussions for Accelerated Approval, New NDA for CNM-Au8(R) in 2024
April 11, 2024
Via
Investor Brand Network
Exposures
Product Safety
Clene Inc. (NASDAQ: CLNN) has Emerged as a Leader in the Neurodegenerative Field Utilizing a Novel Nanotherapeutic Drug
April 09, 2024
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Announces Publication of “Protein Corona Composition of Gold Nanocatalysts” in ACS Pharmacology & Translational Science
April 02, 2024
Via
Investor Brand Network
3 Penny Stocks That Could Be Multibaggers in the Making: March Edition
March 26, 2024
Via
InvestorPlace
Clene Inc. (NASDAQ: CLNN) Announces Operational Highlights for Lead Therapeutic Candidate for ALS and MS
March 26, 2024
Via
Investor Brand Network
New Study Leverages Real-World Data to Assess Differences in Parkinson’s Progression
March 25, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) Work in Nanotechnology Highlighted in ‘First in Human’ Podcast
March 19, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Publication of Peer-Reviewed Research for Investigational Drug CNM-Au8(R)
March 15, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces FY 2023 Results, Recent Operating Highlights
March 13, 2024
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Participation at Upcoming 36th Annual Roth Conference
March 07, 2024
Via
Investor Brand Network
A Comparison Between ALS, Parkinson’s Disease
March 01, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN), Subsidiary Report Positive Clinical Results of CNM-Au8 Treatment at MS Forum
February 29, 2024
Via
Investor Brand Network
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.